My understanding is the evidence base from Scandinavian countries with policies such as this do not demonstrate an increase in drug use after implementation of such policies. Furthermore, this encourages the engagement of disenfranchised patient populations with healthcare professionals, and reduces the risk associated with intravenous drug use such as infective endocarditis. My understanding is the evidence base suggests that, due to the decrease in such diseases, these policies are cost-effective on a population level.